More Data for Ustekinumab in Crohn’s Disease

Posted on by

Briefly noted: C Ma et al. Inflamm Bowel Dis 2017; 23: 833-9.  This retrospective study examined the response to ustekinumab in 104 patients with Crohn’s disease.  All patients had achieved a steroid-free ustekinumab induction.  92.3% had failed anti-TNFα therapy.

Key findings:

  • 71.8% maintained a response at 52 weeks
  • 64.4% maintained an endoscopic or radiographic response

4 thoughts on “More Data for Ustekinumab in Crohn’s Disease”

  1. Didn’t read the article yet, but impressive response rate for anti-TNF failures. I don’t think we have seen that with any other biologic post anti-TNF failure?

    • One reason for the impressive results was that all had undergone an ustekinumab induction and therefore had already responded. This study shows mainly that if one responds to ustekinumab, they are likely to maintain a response.

  2. Pingback: Ustekinumab for Ulcerative Colitis (UNIFI Trial) | gutsandgrowth

  3. Pingback: Dose Escalation of Ustekinumab & Support Tool “Should I Have IBD Surgery?” | gutsandgrowth

Comments are closed.